In vitro comparison of aerosol characteristics of HFA albuterol (salbutamol) pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs)

D. von Hollen, L. Slator, K. Nikander, R. Hatley (Parsippany, United States Of America; Chichester, United Kingdom)

Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Session: Drug delivery and pharmacokinetics II
Session type: Thematic Poster Session
Number: 3989
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. von Hollen, L. Slator, K. Nikander, R. Hatley (Parsippany, United States Of America; Chichester, United Kingdom). In vitro comparison of aerosol characteristics of HFA albuterol (salbutamol) pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs). Eur Respir J 2011; 38: Suppl. 55, 3989

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
In vitro comparison of aerosol characteristics of HFA ipratropium bromide pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Assessment of the suitability of filters for use in clinical studies with an HFA fluticasone propionate pressurized metered dose inhaler (pMDI) and a valved holding chamber (VHC)
Source: Annual Congress 2011 - Lung function today and tomorrow II
Year: 2011

Comparison of proficiency of pressurized metered dose inhaler (pMDI) use with asthma control
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008


In vitro evaluation of spacers in comparison with T-adapters in mechanical ventilation with pressurized metered dose inhalers (pMDI) and vibrating mesh nebulizer.
Source: International Congress 2019 – COPD and other specific entities in intensive care unit medicine
Year: 2019

Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study.
Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils
Year: 2020


In vitro aerosol delivery by vibrating mesh nebulizer (VMN) and pressurized metered dose inhaler (pMDI) using spacers in comparison with T adapters in mechanical ventilation.
Source: Respiratory Failure and Mechanical Ventilation Conference 2020
Year: 2020



Impact of inhalation delay on medication delivery from a salbutamol HFA pressurized metered dose inhaler used with and without a new prototype portable valved holding chamber
Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Year: 2019

Relative pulmonary bioavailability (BA) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) and a novel breath-triggered inhaler (BTI)
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017


Salmeterol metered dose inhaler (MDI) propelled by hydrofluoroalkane (HFA) is non-inferior to salmeterol chlorofluorocarbon (CFC) propelled MDI in paediatic patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 583s
Year: 2004

Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005

Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) delivered by a new soft mist inhaler (SMI) or a conventional metered dose inhaler (MDI) in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Pharmacokinetics (PK) of a single dose AZD7594 administered intravenously (IV), orally, and inhaled via two dry powder inhalers (DPI) and a pressurized metered-dose inhaler (pMDI)
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017

Assessment of relative potency of salbutamol administered via a metered-dose inhaler plus spacer or via a dry-powder inhaler in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 209s
Year: 2006

Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 583s
Year: 2004

Comparison of the safety relating to paradoxical bronchoconstriction of ipratropium bromide (IB) alone or combined with fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (CFC-MDI) in
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002

Comparison of the long-term efficacy and safety of ipratropium bromide (IB) delivered by a new soft mist inhaler (SMI) versus conventional metered dose inhaler (MDI) in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 69s
Year: 2001

Two-tone trainer maintains a slow inhalation rate when using a metered dose inhaler (MDI)
Source: Eur Respir J 2005; 26: Suppl. 49, 47s
Year: 2005

Formoterol via turbuhaler (F) versus salbutamol via pressurized metered-dose inhaler (SB) in acute exacerbations of COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 425s
Year: 2001